Advances in targeted alpha therapy for prostate cancer - ScienceDirect
Cancers | Free Full-Text | PSMA Theranostics: Science and Practice
²²⁵Ac-PSMA-617 and ²²⁵Ac-PSMA-TO-1 mouse overall survival. A... | Download Scientific Diagram
Synthesis of 225Ac-PSMA-617 for Preclinical Use | Bentham Science
PSMAtreatment - What is actinium PSMA - PSMA Forum
Lu-177 PSMA therapy vs Ac-225 PSMA therapy
Lu-177 PSMA therapy vs Ac-225 PSMA therapy
![Cancers | Free Full-Text | [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA -617](https://pub.mdpi-res.com/cancers/cancers-14-05651/article_deploy/html/images/cancers-14-05651-ag.png?1669355153 "Cancers | Free Full-Text | [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA -617")
Cancers | Free Full-Text | [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA -617
![Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00722/article_deploy/html/images/pharmaceutics-13-00722-g002.png "Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis")
Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC | European Journal of Nuclear Medicine and Molecular Imaging
Cureus | A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer | Article
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
Efficacy and safety of Ac-225-PSMA-617 TAT in Prostate Cancer - Oncidium Foundation
225Ac-PSMA-617 for Therapy of Prostate Cancer - ScienceDirect
mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis | Journal of Nuclear Medicine
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer | RadioGraphics
Safety and Activity of Alpha-Emitting Ac-225-PSMA-617 Radioligand Therapy in mCRPC That Has Progressed After Lu-177-PSMA, Journal Club – Christopher Wallis & Zachary Klaassen
![Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/early/2023/08/23/jnumed.123.265546/F1.large.jpg "Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine")
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
A) 68 Ga-PSMA-11 PET/CT scan of patient with pretherapeutic tumor... | Download Scientific Diagram
⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy - ScienceDirect
